Search Results
Your search for Lori J. Wirth, MD matches 14 pages
Showing 1 - 14Advanced RET-Mutant Medullary Thyroid Cancer: First-Line Selpercatinib
As presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA3) and reported in The New England Journal of Medicine by Hadoux et al, an interim analysis from the phase III LIBRETTO-531 trial has shown improved progression-free survival with selpercatinib vs...
Head and Neck Cancers 2022–2023 Almanac
Head and neck cancers comprise approximately 4% of all new cancer diagnoses globally and represent approximately 110,000 new cancer diagnoses and 17,000 cancer deaths annually in the United States. Head and neck cancers are a heterogenous group of malignancies where prognosis and treatment varies...
Receptor Tyrosine Kinase Inhibitor Lenvatinib for Anaplastic Thyroid Cancer
As reported in the Journal of Clinical Oncology by Lori J. Wirth, MD, and colleagues, a phase II trial of lenvatinib in patients with anaplastic thyroid cancer was stopped for futility after an interim analysis. Study Details In the international multicenter trial, 34 patients received lenvatinib...
Lori J. Wirth, MD, on Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options
Lori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion positive, and RET–altered disease; and optimal therapies for patients with multiple types of thyroid...
Selpercatinib Shows Activity in RET Fusion–Positive NSCLC and RET-Altered Thyroid Cancer
As reported inThe New England Journal of Medicine by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues and by Lori J. Wirth, MD, of Massachusetts General Hospital, and colleagues, the phase I/II LIBRETTO-001 trial has shown marked activity of the RET kinase ...
ESMO Congress 2019: Quick Takes From Key Clinical Trials
The ESMO Congress continues to grow as a pivotal platform for research in clinical oncology. At the ESMO Congress 2019, important findings were showcased in more than 2,200 studies, including 93 late-breaking abstracts. The ASCO Post summarized much of that news in separate articles over several...
ESMO 2019: LIBRETTO-001 Trial of Selpercatinib in RET Fusion–Positive Thyroid Cancer
Patients with advanced RET fusion–positive thyroid cancer and RET-mutant medullary thyroid cancer had high rates of response following treatment with selpercatinib, according to findings from the phase I/II LIBRETTO-001 trial presented by Wirth et al at the European Society for Medical Oncology...
Are Thyroid Cancer Incidence and Mortality Rates Truly Increasing in the United States?
THYROID CANCER diagnoses are increasing at a rate faster than any other malignancy in the United States. In 2017, there will be 56,870 new cases, accounting for 3.4% of all cancers, and 2,010 people will die of thyroid cancer.1 This represents a more than 200% increase in incidence since the...
Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. With combined-modality approaches, the chance of cure ranges from < 50% to up to 80%, depending on the site, stage, and other risk factors, such as human papillomavirus (HPV) status. When...
Impressive Delay in Thyroid Cancer Progression Achieved With Lenvatinib
The investigational tyrosine kinase inhibitor lenvatinib reduced disease progression by 79%, as compared to placebo, in patients with metastatic differentiated thyroid cancer that is refractory to radioactive iodine in the phase III SELECT trial. These findings were presented at the 2014 ASCO...
Welcome to Multikinase Inhibitors in Radioiodine-Refractory Thyroid Cancer
In the past 2 decades, the incidence of thyroid cancer has risen steeply, with rates now growing by 5.5% annually.1 In 2014, 62,980 new cases of thyroid cancer were diagnosed in the United States. The good news is that, overall, the prognosis of thyroid cancer remains excellent; 97.8% of patients...
Large Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Thyroid Cancer
In a phase III trial reported in The New England Journal of Medicine, Martin Schlumberger, MD, of Institut Gustave Roussy, and colleagues found that the multikinase inhibitor lenvatinib (Lenvima) produced a large improvement in progression-free survival vs placebo in patients with advanced...
Expert Point of View: Lori J. Wirth, MD
Pembrolizumab [Keytruda] has a more favorable side-effect profile than cytotoxic chemotherapy and cetuximab [Erbitux]. This is particularly important for recurrent/metastatic head and neck cancer patients who have been so beaten up by their disease, the treatment for their disease, and their...
Dabrafenib May Stimulate Radioiodine Uptake in Patients With Iodine-Refractory Papillary Thyroid Cancer
In patients with iodine-refractory papillary thyroid cancer, the addition of dabrafenib (Tafinlar) therapy was shown to stimulate radioiodine uptake in thyroid cancer cells, according to a report by Rothenberg et al in Clinical Cancer Research. This approach has the potential advantage of requiring ...
